MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
Related Experiment Video
Updated: Aug 18, 2026

A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
Conor C Lynch1, Atsuya Hikosaka, Heath B Acuff
1Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA.
Abstract:
We developed a rodent model that mimics the osteoblastic and osteolytic changes associated with human metastatic prostate cancer. Microarray analysis identified MMP-7, cathepsin-K, and apolipoprotein D as being upregulated at the tumor-bone interface. MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing RANKL to a soluble form that promoted osteoclast activation. MMP-7-deficient mice demonstrated reduced prostate tumor-induced osteolysis and RANKL processing. This study suggests that inhibition of MMP-7 will have therapeutic benefit in the treatment of prostate cancer-induced osteolysis.
Related Concept Videos
Role of Matrix Metalloproteases in Degradation of ECM
A...
Osteoclasts in Bone Remodeling
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Abnormal Proliferation
